Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.

Linge A, Kennedy S, O'Flynn D, Beatty S, Moriarty P, Henry M, Clynes M, Larkin A, Meleady P.

Invest Ophthalmol Vis Sci. 2012 Jul 9;53(8):4634-43. doi: 10.1167/iovs.11-9019.

PMID:
22570344
2.

Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.

Coupland SE, Vorum H, Mandal N, Kalirai H, Honoré B, Urbak SF, Lake SL, Dopierala J, Damato B.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):12-20. doi: 10.1167/iovs.09-3913. Epub 2009 Jul 30.

PMID:
19643972
3.

Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.

All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O.

Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8.

PMID:
11773005
4.

Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.

Paraoan L, Gray D, Hiscott P, Ebrahimi B, Damato B, Grierson I.

Exp Eye Res. 2006 Oct;83(4):911-9. Epub 2006 Jun 19.

PMID:
16784742
5.

Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.

Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R.

Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9368-72. doi: 10.1167/iovs.10-6006.

PMID:
22039239
6.

Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression.

Zuidervaart W, Hensbergen PJ, Wong MC, Deelder AM, Tensen CP, Jager MJ, Gruis NA.

Invest Ophthalmol Vis Sci. 2006 Mar;47(3):786-93.

PMID:
16505008
7.

An immunohistochemical analysis of nm23 gene product expression in uveal melanoma.

Greco IM, Calvisi G, Ventura L, Cerrito F.

Melanoma Res. 1997 Jun;7(3):231-6.

PMID:
9195562
8.

Melanoma inhibitory activity: a novel serum marker for uveal melanoma.

Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ.

Melanoma Res. 2002 Dec;12(6):593-9.

PMID:
12459649
9.

Heat shock protein expression in the eye and in uveal melanoma.

Missotten GS, Journée-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ.

Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3059-65.

PMID:
12824252
10.

Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.

López MN, Pereda C, Ramírez M, Mendoza-Naranjo A, Serrano A, Ferreira A, Poblete R, Kalergis AM, Kiessling R, Salazar-Onfray F.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1219-27.

PMID:
17325166
11.

Cripto-1 expression in uveal melanoma: an immunohistochemical study.

Mallikarjuna K, Vaijayanthi P, Krishnakumar S.

Exp Eye Res. 2007 Jun;84(6):1060-6. Epub 2007 Feb 7.

PMID:
17412323
12.

Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis.

Chang SH, Worley LA, Onken MD, Harbour JW.

Melanoma Res. 2008 Jun;18(3):191-200. doi: 10.1097/CMR.0b013e3283005270.

PMID:
18477893
13.

Proteomics in uveal melanoma.

Ramasamy P, Murphy CC, Clynes M, Horgan N, Moriarty P, Tiernan D, Beatty S, Kennedy S, Meleady P.

Exp Eye Res. 2014 Jan;118:1-12. doi: 10.1016/j.exer.2013.09.005. Epub 2013 Sep 19. Review.

PMID:
24056206
14.

c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?

All-Ericsson C, Girnita L, Müller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O.

Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2075-82.

PMID:
15223779
15.

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.

Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD.

PLoS One. 2015 Aug 25;10(8):e0135543. doi: 10.1371/journal.pone.0135543. eCollection 2015.

16.

[Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].

Schaller UC, Mueller AJ, Bosserhoff AK, Haraida S, Löhrs U, Buettner R, Kampik A.

Ophthalmologe. 2000 Jun;97(6):429-32. German.

PMID:
10916387
18.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
19.

Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas.

Sahin A, Kiratli H, Soylemezoglu F, Tezel GG, Bilgic S, Saracbasi O.

Jpn J Ophthalmol. 2007 Sep-Oct;51(5):325-31. Epub 2007 Oct 5.

PMID:
17926107
20.

Differential expression of chemokine receptors on uveal melanoma cells and their metastases.

Li H, Alizadeh H, Niederkorn JY.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43. doi: 10.1167/iovs.07-1035.

PMID:
18235009

Supplemental Content

Support Center